Henry Schein (HSIC) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Henry Schein (HSIC) has outperformed Veracyte (VCYT) over the past year, gaining 30.7% versus a gain of 24.2%. Over five years, HSIC leads with a +9.3% price change compared with -3.5% for VCYT. Henry Schein is the larger company by market cap ($9.35 billion vs $3.66 billion), about 2.6 times the size, while Veracyte is growing revenue faster (+16.0% vs +4.0%).
On valuation, Henry Schein trades at a lower forward P/E (14.0x vs 23.4x for Veracyte). Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus 3.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HSIC | VCYT |
|---|---|---|
| Share price | $83.94 | $45.50 |
| Market cap | $9.35B | $3.66B |
| 1-day change | -0.82% | +4.35% |
| YTD return | +11.97% | +3.56% |
| 1-year return | +30.74% | +24.22% |
| 5-year return | +9.28% | -3.45% |
| P/E ratio (TTM) | 24.47 | 32.50 |
| Forward P/E | 14.03 | 23.39 |
| EPS (TTM) | $3.43 | $1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.18B | $517.14M |
| Revenue growth (YoY) | +4.03% | +16.01% |
| Net income (latest FY) | $398.00M | $66.35M |
| Gross margin | 31.14% | 70.10% |
| Operating margin | 4.95% | 11.17% |
| Net margin | 3.02% | 12.83% |
| 52-week high | $92.18 | $60.91 |
| 52-week low | $61.95 | $29.46 |
| Distance from 52-week high | -8.94% | -25.30% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +15.88% | +28.40% |
| Average volume | 1.22M | 1.36M |
| Shares outstanding | 111.45M | 80.39M |
| Employees | 25,000 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Henry Schein is about 2.6 times larger than Veracyte by market value ($9.35B vs $3.66B).
- Veracyte trades at a higher earnings multiple (32.5x vs 24.5x trailing P/E).
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus 3.0 cents for Henry Schein.
- Veracyte grew revenue faster in its latest fiscal year (+16.01% vs +4.03%).
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
HSIC vs VCYT FAQ
Which is bigger, Henry Schein or Veracyte?
Henry Schein (HSIC) is larger, with a market capitalization of $9.35B compared with $3.66B for Veracyte (VCYT).
Which stock has performed better over the past year, HSIC or VCYT?
HSIC returned +30.74% over the past 12 months, compared with +24.22% for VCYT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HSIC or VCYT?
HSIC has the lower trailing P/E at 24.5, versus 32.5 for VCYT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Henry Schein and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.